🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Hikal Limited HIKAL NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.hikal.com

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

READ MORE ›
₹195.28
-47.28% 1Y

Market & Price

Market Cap
₹2,407.82 Cr
Current Price
₹195.28
High / Low (52W)
₹377.61 / ₹147.08
Beta
-

Valuation

Stock P/E
-
Industry PE
37.60
Forward P/E
17.59
PEG Ratio
-
Book Value
₹97.40
Price to Book
2.00
P/S
2.00
EV/EBITDA
-
Dividend Yield
0.51%

Profitability & Returns

ROCE
-0.96%
ROE
-
ROA
-
Profit Margin
6.15%
Op Margin
13.16%
EPS (Latest Qtr)
₹1.17
EPS (TTM)
₹-3.96

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
₹2,365.40 Cr
Current Assets
₹884.10 Cr
Working Capital
₹205.20 Cr

Ownership

Promoter Holding
69.10%
Chg in Prom Hold
-
FII / Inst Holding
7.85%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
₹1,203.61 Cr
EBITDA
₹223.76 Cr
Free Cash Flow
-
Operating Cash Flow
-
Shares Outstanding
₹12.33 Cr
Gross Margin
47.01%
Payout Ratio
172.84%

Growth (CAGR)

Revenue 5Y
-5.44%
Profit 5Y
-54.09%
Revenue (YoY)
37.30%
Earnings (YoY)
68.30%

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -5.4% CAGR over 5 years.
  • Earnings shrank at -54.1% CAGR over 5 years.
  • Trading 48.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 HIKAL Hikal Limited NSEPHARMA 195.28 - ₹2,407.82 Cr 0.51% -0.96% - -5.44% -54.09%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --550.00 Cr371.30 Cr316.20 Cr490.70 Cr517.00 Cr
Cost of Revenue --232.20 Cr186.80 Cr126.30 Cr232.00 Cr216.60 Cr
Gross Profit --317.80 Cr184.50 Cr189.90 Cr258.70 Cr300.40 Cr
Operating Expenses --232.10 Cr198.80 Cr223.90 Cr217.20 Cr237.00 Cr
Operating Income --85.70 Cr-14.30 Cr-34.00 Cr41.50 Cr63.40 Cr
EBITDA --123.90 Cr26.10 Cr9.10 Cr47.50 Cr64.90 Cr
Interest Expense --17.90 Cr17.10 Cr14.90 Cr15.50 Cr14.60 Cr
Pretax Income --68.30 Cr-30.40 Cr-47.00 Cr-9.20 Cr8.30 Cr
Tax Provision --18.10 Cr-8.00 Cr-12.10 Cr-3.30 Cr-6.10 Cr
Net Income --50.20 Cr-22.40 Cr-34.90 Cr-5.90 Cr14.40 Cr
Diluted EPS 1.48-4.07-1.82-2.83-0.481.17

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -2,004.70 Cr1,768.70 Cr1,843.50 Cr1,695.20 Cr
Cost of Revenue -1,142.27 Cr864.10 Cr837.30 Cr761.70 Cr
Gross Profit -862.44 Cr904.60 Cr1,006.20 Cr933.50 Cr
Operating Expenses -713.51 Cr755.00 Cr812.20 Cr876.90 Cr
Operating Income -148.93 Cr149.60 Cr194.00 Cr56.60 Cr
EBITDA -255.31 Cr266.30 Cr333.40 Cr147.60 Cr
Interest Expense -40.93 Cr53.20 Cr75.20 Cr62.10 Cr
Pretax Income -105.36 Cr95.50 Cr123.80 Cr-78.30 Cr
Tax Provision -26.98 Cr25.90 Cr33.00 Cr-29.50 Cr
Net Income -78.38 Cr69.60 Cr90.80 Cr-48.80 Cr
Diluted EPS 13.026.365.647.36-

Compounded Sales Growth

5 Years:-5.44%
1 Year:37.30%

Compounded Profit Growth

5 Years:-54.09%
1 Year:68.30%

Stock Price Performance

1 Year:-47.28%
6 Months:-10.83%
3 Months:-2.63%
1 Month:+3.19%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -2,385.48 Cr2,487.10 Cr2,528.90 Cr2,365.40 Cr
Current Assets -939.02 Cr966.60 Cr995.40 Cr884.10 Cr
Cash & Equivalents -26.73 Cr12.70 Cr13.00 Cr9.60 Cr
Inventory -316.74 Cr303.70 Cr334.50 Cr358.10 Cr
Receivables -441.78 Cr550.30 Cr522.40 Cr441.60 Cr
Total Liabilities -1,252.01 Cr1,299.40 Cr1,266.60 Cr1,166.60 Cr
Current Liabilities -661.55 Cr756.60 Cr789.50 Cr678.90 Cr
Long Term Debt -489.88 Cr422.90 Cr367.20 Cr373.10 Cr
Total Debt -748.18 Cr817.60 Cr764.70 Cr683.80 Cr
Total Equity -1,133.47 Cr1,187.70 Cr1,262.30 Cr1,198.80 Cr
Shares Outstanding -12.33 Cr12.33 Cr12.33 Cr12.33 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -315.31 Cr186.70 Cr280.40 Cr302.00 Cr
Investing Cash Flow --292.34 Cr-173.70 Cr-136.50 Cr-145.30 Cr
Financing Cash Flow --7.68 Cr-27.00 Cr-143.60 Cr-160.10 Cr
Capital Expenditure --302.62 Cr-204.20 Cr-137.30 Cr-148.10 Cr
Free Cash Flow -12.69 Cr-17.50 Cr143.10 Cr153.90 Cr
Net Change in Cash -15.29 Cr-14.00 Cr30.00 L-3.40 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -43.0%51.1%54.6%55.1%
Operating Margin % -7.4%8.5%10.5%3.3%
Net Margin % -3.9%3.9%4.9%-2.9%
ROE % -6.9%5.9%7.2%-4.1%
ROCE % -8.6%8.6%11.2%3.4%

Shareholding Pattern

Insiders
69.10%
Institutions
7.85%
Public Float
25.42%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HIKAL

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space